Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products … Read more
Zhejiang Shouxiangu Pharm Co (603896) - Net Assets
Latest net assets as of September 2025: CN¥2.31 Billion CNY
Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) has net assets worth CN¥2.31 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.15 Billion) and total liabilities (CN¥841.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.31 Billion |
| % of Total Assets | 73.31% |
| Annual Growth Rate | 26.37% |
| 5-Year Change | 72.96% |
| 10-Year Change | 522.48% |
| Growth Volatility | 35.21 |
Zhejiang Shouxiangu Pharm Co - Net Assets Trend (2012–2024)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Shouxiangu Pharm Co (2012–2024)
The table below shows the annual net assets of Zhejiang Shouxiangu Pharm Co from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.29 Billion | +5.65% |
| 2023-12-31 | CN¥2.17 Billion | +13.95% |
| 2022-12-31 | CN¥1.91 Billion | +17.62% |
| 2021-12-31 | CN¥1.62 Billion | +22.15% |
| 2020-12-31 | CN¥1.33 Billion | +13.12% |
| 2019-12-31 | CN¥1.17 Billion | +19.06% |
| 2018-12-31 | CN¥984.74 Million | +13.22% |
| 2017-12-31 | CN¥869.75 Million | +99.06% |
| 2016-12-31 | CN¥436.93 Million | +18.56% |
| 2015-12-31 | CN¥368.53 Million | +14.96% |
| 2014-12-31 | CN¥320.56 Million | +7.03% |
| 2013-12-31 | CN¥299.50 Million | +116.45% |
| 2012-12-31 | CN¥138.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Shouxiangu Pharm Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5429.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.07 Billion | 46.74% |
| Common Stock | CN¥198.24 Million | 8.64% |
| Other Comprehensive Income | CN¥219.08 Million | 9.55% |
| Other Components | CN¥804.52 Million | 35.07% |
| Total Equity | CN¥2.29 Billion | 100.00% |
Zhejiang Shouxiangu Pharm Co Competitors by Market Cap
The table below lists competitors of Zhejiang Shouxiangu Pharm Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DONGGUAN R.COMMERC. H YC1
F:857
|
$307.20 Million |
|
Jiangsu Tongli Risheng Machinery Co. Ltd.
SHG:605286
|
$307.28 Million |
|
Hanza AB
ST:HANZA
|
$307.34 Million |
|
Thai Vegetable Oil Public Company Limited
BK:TVO
|
$307.39 Million |
|
Lindex Group
HE:LINDEX
|
$307.12 Million |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
$307.06 Million |
|
Facc AG
VI:FACC
|
$307.05 Million |
|
Alpargatas S.A
SA:ALPA3
|
$307.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Shouxiangu Pharm Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,171,288,696 to 2,294,019,344, a change of 122,730,648 (5.7%).
- Net income of 174,714,540 contributed positively to equity growth.
- Dividend payments of 83,001,932 reduced retained earnings.
- Other comprehensive income increased equity by 126,254,168.
- Other factors decreased equity by 95,236,128.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥174.71 Million | +7.62% |
| Dividends Paid | CN¥83.00 Million | -3.62% |
| Other Comprehensive Income | CN¥126.25 Million | +5.5% |
| Other Changes | CN¥-95.24 Million | -4.15% |
| Total Change | CN¥- | 5.65% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Shouxiangu Pharm Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.14x to 1.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.32 | CN¥19.96 | x |
| 2013-12-31 | CN¥2.85 | CN¥19.96 | x |
| 2014-12-31 | CN¥2.35 | CN¥19.96 | x |
| 2015-12-31 | CN¥2.72 | CN¥19.96 | x |
| 2016-12-31 | CN¥3.20 | CN¥19.96 | x |
| 2017-12-31 | CN¥5.34 | CN¥19.96 | x |
| 2018-12-31 | CN¥5.35 | CN¥19.96 | x |
| 2019-12-31 | CN¥6.41 | CN¥19.96 | x |
| 2020-12-31 | CN¥7.20 | CN¥19.96 | x |
| 2021-12-31 | CN¥8.37 | CN¥19.96 | x |
| 2022-12-31 | CN¥9.90 | CN¥19.96 | x |
| 2023-12-31 | CN¥11.09 | CN¥19.96 | x |
| 2024-12-31 | CN¥11.57 | CN¥19.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Shouxiangu Pharm Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.62%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.26%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.36x
- Recent ROE (7.62%) is below the historical average (14.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 24.59% | 19.14% | 0.65x | 1.98x | CN¥20.19 Million |
| 2013 | 18.05% | 21.36% | 0.62x | 1.37x | CN¥24.10 Million |
| 2014 | 21.60% | 22.96% | 0.60x | 1.56x | CN¥37.19 Million |
| 2015 | 17.00% | 20.75% | 0.50x | 1.64x | CN¥25.79 Million |
| 2016 | 18.53% | 25.72% | 0.51x | 1.40x | CN¥37.29 Million |
| 2017 | 10.22% | 24.02% | 0.40x | 1.07x | CN¥1.91 Million |
| 2018 | 10.93% | 21.05% | 0.43x | 1.21x | CN¥9.18 Million |
| 2019 | 10.57% | 22.66% | 0.41x | 1.14x | CN¥6.65 Million |
| 2020 | 11.44% | 23.85% | 0.37x | 1.28x | CN¥19.08 Million |
| 2021 | 12.40% | 26.18% | 0.39x | 1.21x | CN¥38.86 Million |
| 2022 | 14.58% | 33.51% | 0.29x | 1.50x | CN¥87.23 Million |
| 2023 | 11.72% | 32.44% | 0.25x | 1.46x | CN¥37.35 Million |
| 2024 | 7.62% | 25.26% | 0.22x | 1.36x | CN¥-54.69 Million |
Industry Comparison
This section compares Zhejiang Shouxiangu Pharm Co's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Shouxiangu Pharm Co (603896) | CN¥2.31 Billion | 24.59% | 0.36x | $307.16 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |